On the stock market since 2018, it operates in the world of health and science. It has 22 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
An average decline of 48% a year over the last 4 years — the most striking risk in this picture. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
Executives buying with their own money is usually read as confidence in the company’s future.
angles, checked one by one.
The 2 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Cost Efficiency: As sales grow, profit fails to keep the same pace.
The stock trades 38% below its peak. The market has trimmed its expectations for the company.
Sales run at $42K a year. A small number, but proof the product has real buyers.
Over the last 12 months, company executives reported 33 buys and 0 sells. Management buying with its own money is usually read as a good sign.
A loss of $11.4M against $42K in annual sales. And on top of that, sales fell from the year before.
At the current pace of spending, the cash lasts less than a year. After that, the company needs to find new money.
On our five-subject report card, ENTX sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: ENTX is a high-risk stock — not yet profitable, and its future rides on its product catching on.